In October 2025, the White House announced two significant developments aimed at improving IVF affordability and access nationwide. These changes—focused on lowering fertility medication costs and giving employers greater flexibility to offer fertility benefits—could reshape how reproductive care is delivered and covered in the workplace.
Fertility Drug Discounts: EMD Serono & TrumpRx
The Trump administration struck a deal with EMD Serono that would allow popular fertility medications—such as Gonal-F®, Ovidrel®, and Cetrotide®—to be offered at a combined 84% discount off list price when purchased as part of an IVF package.
According to the White House, these drug discounts could save patients up to $2,200 per IVF cycle, targeting one of the costlier elements in fertility treatment.
EMD Serono’s announcement confirms that these discounted drug purchases will be facilitated via a new government platform called TrumpRx.gov, launching in 2026, and through existing pharmacy networks.
Fertility Benefit Flexibility for Employers
Alongside drug pricing reforms, the administration also introduced guidance allowing employers to offer standalone fertility benefits, separate from major medical plans—much like dental or vision coverage.
These updated rules are intended to make it easier for employers, including smaller ones, to offer fertility support without restructuring health plan architecture.
However, it’s important to note the policymakers stopped short of mandating coverage or introducing subsidies; participation will remain voluntary.
Current Landscape: Fertility Benefits in U.S. Employer Plans
More than 4 in 10 U.S. employers (42%) now provide fertility coverage, rising from 30% in 2020. AJMC
These numbers suggest that fertility and family-forming benefits are becoming more common—and more feasible—for employers of all sizes.
What This Means for Employers & Benefits Design
For Employees & Families
- Reduced drug costs could make IVF cycles more affordable for many.
- Greater choice of fertility benefits via employer programs may ease access in markets where coverage is limited.
For Employers & Benefits Leaders
- Opportunity to expand fertility benefits in a scalable, flexible way.
- Potential to differentiate benefits offerings and attract/retain fertility-age talent.
- Need to monitor usage, ROI, and impacts on plan spend over time.
- Importance of aligning benefit design, vendor selection, and communication strategies to maximize uptake and value.
ARC Fertility Is Positioned to Lead
ARC Fertility has long championed evidence-based, cost-effective family-forming solutions through:
- Bundled packages pricing models for IVF and related services
- A superior, vetted national network of reproductive care providers
- Care navigation to help employees navigate treatment decisions and benefit use
- Inclusive coverage across family-building paths
With the new policy environment emerging, ARC is ready to support employers in deploying flexible fertility benefit strategies, integrating drug discount programs, and managing benefit design complexity.
The Future of Fertility Care & Workplace Benefits
These newly announced reforms—from steep drug discounts to expanded employer flexibility—represent a turning point in the fertility care landscape. For many, they reduce two of the largest financial and structural barriers to accessing IVF and assisted reproductive treatment.
Yet the impact will depend heavily on implementation details: which employers adopt supplemental benefit plans, how benefit design evolves, and whether the drug discounts reach the people who need them most.
For employers ready to strengthen benefits and improve IVF affordability and access, ARC Fertility offers proven, cost-effective strategies to make reproductive care inclusive and attainable for all employees.
Contact ARC Fertility today to explore how your organization can adapt to this new policy landscape and lead with care.
